The blockade of the renin-angiotensin system reverses tacrolimus related cardiovascular toxicity at the histopathological level

Abstract

Introduction. In this study, we investigate the toxic effects of tacrolimus (FK506) on the cardiovascular system at the histopathological level in a rat model and whether these effects can be reversed by the blockade of the renin-angiotensin system (RAS) by either an angiotensin-converting enzyme inhibitor (ACE-inhibitors) or an angiotensin receptor antagonist (ARB).

Methods and results. Thirty-one Wistar rats were divided into four groups. FK506 group was treated with FK506 intraperitoneally (i.p.), FK506+ACE-inhibitors and FK506+ARB groups were treated with either quinapril or valsartan orally in addition to FK506. Control group was treated with saline i.p. Histological and immunohistochemical staining of cardiovascular tissue in the FK506 group showed increased vacuolar degeneration (11.2 vs. 5.8, p=0.008), arterial hyalinosis (10.7 vs. 6. G 3, p=0.036), transforming growth factor-beta (TGF-β) (12.2 vs. 4.8, p=0.001) and vascular endothelial growth factor expression (VEGF) (10.7 vs. 6.3, p=0.036), elastic van Gieson (11.5 vs. 5.5, p=0.004), and periodic acid O Schiff stain scores (12.5 vs. 4.5, p<0.001) compared to the control group. Immunohistochemical scores showed that expression of TGF-β is up-regulated, and bone morphogenic protein (BMP-7) is down-regulated with FK506 toxicity. Adding RAS blockade with either an ACE-inhibitor or an ARB could reverse FK506 induced changes. Both FK506+ACE-inhibitors and FK506+ARB groups demonstrated decrease in arterial hyalinosis (22.1 vs. 14.4 (FK506+ACE-inhibitor) and 13.6 (FK506+ARB), p=0.09) and vacuolar degeneration (23.1 vs. 16.1 (FK506+ACE-inhibitor) and 12.4 (FK506+ARB), p=0.006) scores compared to the FK506 group.

Conclusion. Blockade of RAS could reverse the histopathological signs of FK506 induced cardiac toxicity in a rat model.

Keywords

tacrolimus cardiac toxicity renin-angiotensin system

Get full access to this article

View all access options for this article.

References

Liu J. , Farmer JD , Lane WS , Friedman J. , Weissman I. , Schreiber S. Calcineurin is a common target of cyclophilin-Cyclosporin A and FKBP-FK506 complexes. Cell 1991; 66:807-15.

Dumont FJ FK506, an immunosuppressant targeting calcineurin function. Curr Medic Chem 2000;7:731-48.

Sawabe T. , Mizuno S. , Gondo H. , Maruyama T. , Niho Y. Sinus arrest during tacrolimus (FK506) and digitalis treatment in a bone marrow transplant recipient. Transplantation 1997 ;64:182-3.

Cox TH , Baillie GM , Baliga P. Bradycardia associated with intravenous administration of tacrolimus in a liver transplant recipient. Pharmacotherapy 1997;17:1328-30.

Hodak SP , Moubarak JB , Rodriguez I. , Gelfand MC , Alijani MR , Tracy CM QT prolongation and near fatal cardiac arrhythmia after intravenous tacrolimus administration: a case report. Transplantation 1998;66:535-7.

Atkison P. , Joubert G. , Barron AD et al. Hypertrophic cardiomyopathy associated with tacrolimus in paediatric transplant patients. Lancet 1995;345:894-6.

Jeong HJ , Kim YS , Hong IC Vascular endothelin, TGF-beta, and PDGF expression in FK506 nephrotoxicity of rats, Transplant Proc 1998;30:3596-7.

Khanna A. , Plummer M. , Bromberek C. , Bresnahan B. , Hariharan S. Expression of TGF-beta and fibrogenic genes in transplant recipients with tacrolimus and cyclosporine nephrotoxicity. Kidney Int 2002;62:2257-63.

Andoh TF , Burdmann EA , Lindsley J. , Houghton DC , Bennett WM Enhancement of FK 506 nephrotoxicity by sodium depletion in an experimental rat model. Transplantation 1994;27:483-9.

10.

Hanawa H. , Kodama M. , Zhang S. , Izumi T. , Shibata A. An immunosuppressant compound, FK506, prevents the progression of autoimmune myocarditis in rats. Clin Immunol Immunopathol 1992;62:321-6.

11.

Saad SY , Najjar TAO , Alashari M. Cardiotoxicity of doxorubicin/paclitaxel combination in rats: Effect of sequence and timing of administration. J Biochem Mol Toxicol 2004;18:78-86.

12.

McAllister HA Endomyocardial biopsy in the evaluation of conditions leading to cardiac transplantation and in the evaluation of cardiac allograft rejection. Texas Heart Ins J 1995 ;22:53-66.

13.

Fischer VW , Barner HB , Larose LS Pathomorphologic aspects of muscular tissue in diabetes mellitus. Hum Pathol 1984;15:1127-36.

14.

Nunoda S. , Genda A. , Sugihara N. , Nakayama A. , Mizuno S. , Takeda R. Quantitative approach to the histopathology of the biopsied right ventricular myocardium in patients with diabetes mellitus. Heart Vessels 1985;1:43-7.

15.

Euler-Taimor G. , Heger J. The complex pattern of SMAD signaling in the cardiovascular system. Cardiovascular Research 2006;69:15-25.

16.

Wang S. , Hirschberg R. Bone morphogenetic protein-7 signals opposing transforming growth factor beta in mesangial cells. J Biol Chem 2004;279:23200-06.

17.

Kagami S. , Border WA , Miller DE , Noble NA Angiotensin II stimulates extracellular matrix protein synthesis through induction of transforming growth factor-beta expression in rat glomerülar mesengial cells. J Clin Invest 1994;93:2431-7.

18.

Branton MH , Kopp JB TGF-beta and fibrosis. Microbes Infect 1999 ;1:1349-65.

19.

Tuglular S. , Gogas-Yavuz D. , Cakalagaoglu F. et al. Cyclosporine-A induced nephrotoxicity is associated with decreased renal bone morphogenetic protein-7 expression in rats. Transplant Proc 2004;36:131-3.

20.

Ikehara K. , Tada H. , Kuboki K. , Inokuchi T. Role of protein kinase C-angiotensin II pathway for extracellular matrix production in cultured human mesangial cells exposed to high glucose levels. Diabetes Res Clin Pract 2003;59:25-30.

21.

Hao J. , Wang B. , Jones SC , Jassal DS , Dixon IM Interaction between angiotensin II and Smad proteins in fibroblasts in failing heart and in vitro. Am J Physiol Heart Circ Physiol 2000;279:H3020-H30.

22.

Nehme J. , Mercier N. , Labat C. et al. Differences between cardiac and arterial fibrosis and stiffness in aldosterone-salt rats: effect of eplerenone. JRAAS 2006;7:31-9.

23.

R Tamada S. , Asai T. , Kuwabara N. et al. Molecular mechanisms and therapeutic strategies of chronic renal injury: The role of Nuclear Factor κB activation in the development of renal fibrosis. J Pharmacol Sci 2006; 100:17-21.

24.

Gregor P. , Widimsky P. , Rostlapil J. , Cervenka V. , Visek V. Echocardiographic picture in diabetes mellitus. Jpn Heart J 1984;25:969-77.

25.

Laskow DA , Neylan JF 3rd , Shapiro RS , Pirsch JD , Vergne-Marini PJ , Tomlanovich SJ The role of tacrolimus in adult kidney transplantation: a review. Clin Transplant 1998;12:489-503.